You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Trametinib dimethyl sulfoxide - Generic Drug Details

✉ Email this page to a colleague

What are the generic sources for trametinib dimethyl sulfoxide and what is the scope of freedom to operate?

Trametinib dimethyl sulfoxide is the generic ingredient in two branded drugs marketed by Novartis and Novugen, and is included in three NDAs. There are nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Trametinib dimethyl sulfoxide has one hundred and sixty-nine patent family members in forty-six countries.

One supplier is listed for this compound.

Summary for trametinib dimethyl sulfoxide

International Patents:	169
US Patents:	9
Tradenames:	2
Applicants:	2
NDAs:	3
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	55
Clinical Trials:	15
Patent Applications:	264
DailyMed Link:	trametinib dimethyl sulfoxide at DailyMed

Recent Clinical Trials for trametinib dimethyl sulfoxide

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
ECOG-ACRIN Cancer Research Group	Phase 2
Pediatric Brain Tumor Consortium	Phase 1/Phase 2
National Cancer Institute (NCI)	Phase 3

See all trametinib dimethyl sulfoxide clinical trials

Pharmacology for trametinib dimethyl sulfoxide

Drug Class	Kinase Inhibitor
Mechanism of Action	Protein Kinase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for trametinib dimethyl sulfoxide

Paragraph IV (Patent) Challenges for TRAMETINIB DIMETHYL SULFOXIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
MEKINIST	Tablets	trametinib dimethyl sulfoxide	0.5 mg and 2 mg	204114	1	2023-09-28

US Patents and Regulatory Information for trametinib dimethyl sulfoxide

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	MEKINIST	trametinib dimethyl sulfoxide	TABLET;ORAL	204114-001	May 29, 2013		RX	Yes	No	⤷ Subscribe	⤷ Subscribe			Y	⤷ Subscribe
Novugen	TRAMETINIB DIMETHYL SULFOXIDE	trametinib dimethyl sulfoxide	TABLET;ORAL	219002-001	Aug 6, 2024		DISCN	No	No	⤷ Subscribe	⤷ Subscribe				⤷ Subscribe
Novartis	MEKINIST	trametinib dimethyl sulfoxide	TABLET;ORAL	204114-003	May 29, 2013		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe				⤷ Subscribe
Novartis	MEKINIST	trametinib dimethyl sulfoxide	TABLET;ORAL	204114-003	May 29, 2013		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe				⤷ Subscribe
Novartis	MEKINIST	trametinib dimethyl sulfoxide	TABLET;ORAL	204114-001	May 29, 2013		RX	Yes	No	⤷ Subscribe	⤷ Subscribe			Y	⤷ Subscribe
Novartis	MEKINIST	trametinib dimethyl sulfoxide	SOLUTION;ORAL	217513-001	Mar 16, 2023		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for trametinib dimethyl sulfoxide

Subscribe to access the full database, or Subscribe
Country	Patent Number	Title	Estimated Expiration
Japan	2014510704		⤷ Subscribe
Spain	2930157		⤷ Subscribe
Spain	2900825		⤷ Subscribe
Slovenia	2654736		⤷ Subscribe
Slovenia	1761528		⤷ Subscribe
South Korea	100883289		⤷ Subscribe
>Country	>Patent Number	>Title	>Estimated Expiration

Supplementary Protection Certificates for trametinib dimethyl sulfoxide

Subscribe to access the full database, or Subscribe
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1761528	565	Finland	⤷ Subscribe
1761528	C01761528/01	Switzerland	⤷ Subscribe	PRODUCT NAME: TRAMETINIB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65883 22.02.2016
1761528	14C0083	France	⤷ Subscribe	PRODUCT NAME: TRAMETINIB,EVENTUELLEMENT SOUS LA FORME D'UN SEL,HYDRATE OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/14/931 20140630
1761528	68/2014	Austria	⤷ Subscribe	PRODUCT NAME: TRAMETINIB, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH VERTRAEGLICHEN SALZES, HYDRATS ODER SOLVATS DAVON; REGISTRATION NO/DATE: EU/1/14/931 (MITTEILUNG) 20140702
1761528	SPC/GB14/081	United Kingdom	⤷ Subscribe	PRODUCT NAME: TRAMETINIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACEPTABLE SALT, HYDRATE OR SOLVATE THEREOF.; REGISTERED: UK EU/1/14/931(01-06) 20140702
1761528	C20140036 00120	Estonia	⤷ Subscribe	CHANGE OF OWNER'S ADDRESS
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Trametinib dimethyl sulfoxide Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Trametinib Dimethyl Sulfoxide (Mekinist)

Introduction

Trametinib, marketed as Mekinist, is a potent inhibitor of mitogen-activated extracellular signal-regulated kinase 1 and 2 (MEK1 and MEK2), developed by GlaxoSmithKline (GSK). It is primarily used in the treatment of patients with unresectable or metastatic melanoma with BRAF V600 mutations. Here, we delve into the market dynamics and financial trajectory of trametinib.

Mechanism of Action and Therapeutic Indication

Trametinib works by inhibiting the MEK1 and MEK2 kinases, which are part of the BRAF pathway. BRAF V600 mutations lead to the constitutive activation of this pathway, resulting in uncontrolled cellular proliferation in tumors. By inhibiting MEK, trametinib reduces this proliferation, making it an effective treatment for melanoma patients with these specific mutations[4].

Clinical Efficacy and Approval

The clinical efficacy of trametinib was established through several trials, notably the MEK114267 trial, which showed a statistically significant improvement in progression-free survival (PFS) compared to chemotherapy. Patients treated with trametinib had a median PFS of 4.8 months, significantly better than the 1.5 months observed in the chemotherapy arm[5].

Trametinib received FDA approval in 2013 for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations. This approval was based on the clinical trials that demonstrated its efficacy and safety profile[2].

Market Positioning

Trametinib is often used in combination with other drugs, such as dabrafenib, another BRAF inhibitor. This combination therapy has shown enhanced efficacy in treating melanoma patients. The combination of 150 mg dabrafenib plus 2 mg trametinib has been particularly effective, with a higher overall response rate (ORR) compared to monotherapy[5].

Safety Profile and Adverse Events

While trametinib has shown significant clinical benefits, it is associated with several adverse events. Common side effects include rash, diarrhea, fatigue, peripheral edema, nausea, and dermatitis acneiform. More serious safety concerns include cardiac issues such as cardiomyopathy and ocular adverse events like blurry vision and retinal vein occlusion[4].

Market Dynamics

The market for trametinib is influenced by several factors:

Competitive Landscape

The market for MEK inhibitors is competitive, with other drugs like cobimetinib and binimetinib also available. However, trametinib's approval and established efficacy in combination with dabrafenib have secured its position as a leading treatment option for BRAF-mutant melanoma[4].

Patient Population

The patient population for trametinib is specific, targeting those with unresectable or metastatic melanoma and BRAF V600 mutations. This specificity, while limiting the market size, ensures a dedicated patient base for the drug.

Regulatory Environment

Regulatory approvals and compliance play a crucial role in the market dynamics of trametinib. The drug has received approvals in multiple territories, including the U.S., EU, and Australia, which has expanded its market reach[5].

Financial Trajectory

Revenue Growth

Since its approval, trametinib has contributed significantly to GSK's revenue. The combination therapy with dabrafenib has been a key driver of sales, given its enhanced efficacy and broader patient base.

Market Size and Opportunity

The market opportunity for trametinib is substantial, particularly in the context of combination therapies. The estimated market size for targeted therapies in melanoma is growing, driven by the increasing incidence of melanoma and the need for effective treatments.

Cost and Pricing

The cost of trametinib is a significant factor in its market dynamics. Given its efficacy and the lack of alternative treatments for BRAF-mutant melanoma, the drug is priced accordingly. However, this can be a barrier to access in some markets, affecting its financial trajectory.

Research and Development

Continuous research and development are crucial for maintaining and expanding the market for trametinib. GSK and other pharmaceutical companies are investing in clinical trials to explore new indications and combination therapies, which can further enhance the drug's market position.

Key Takeaways

Trametinib is a highly effective MEK inhibitor for treating BRAF-mutant melanoma.
Its approval and established efficacy in combination with dabrafenib have secured its market position.
The drug is associated with specific adverse events, which must be managed.
The market is influenced by regulatory approvals, patient population, and competitive landscape.
The financial trajectory is positive, driven by revenue growth and expanding market opportunities.

FAQs

What is the primary indication for trametinib?

Trametinib is primarily indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations[4].

How does trametinib work?

Trametinib works by inhibiting the MEK1 and MEK2 kinases, which are part of the BRAF pathway, thereby reducing uncontrolled cellular proliferation in tumors[4].

What are the common adverse events associated with trametinib?

Common adverse events include rash, diarrhea, fatigue, peripheral edema, nausea, and dermatitis acneiform. More serious concerns include cardiac and ocular adverse events[4].

Is trametinib used in combination with other drugs?

Yes, trametinib is often used in combination with dabrafenib, another BRAF inhibitor, which has shown enhanced efficacy in treating melanoma patients[5].

What is the current market status of trametinib?

Trametinib has received approvals in multiple territories and is a leading treatment option for BRAF-mutant melanoma, contributing significantly to GSK's revenue[5].

Sources

Australian Public Assessment Report for Trametinib - Therapeutic Goods Administration[1].
FDA NDA 204114: Trametinib - U.S. Food and Drug Administration[2].
Deciphera ESMO 2022 Investor Event - Deciphera Pharmaceuticals[3].
Clinical Pharmacology Review of Trametinib - U.S. Food and Drug Administration[4].
Product Information for Mekinist (Trametinib) - GlaxoSmithKline Australia Pty Ltd[5].

More… ↓

⤷ Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.